Drug Use-Results Survey of Betanis Tablets in Japan
NCT01919047 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10711
Last updated 2015-10-05
Summary
This study is to determine the following information.
1. The occurrence of adverse drug reactions in clinical settings.
2. Factors potentially impacting safety, effectiveness, and other aspects.
Conditions
Interventions
- DRUG
-
Betanis
Oral
Sponsors & Collaborators
-
Astellas Pharma Inc
lead INDUSTRY
Principal Investigators
-
Central Contact · Astellas Pharma Inc
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-04-30
- Primary Completion
- 2014-07-31
- Completion
- 2014-07-31
Countries
- Japan
Study Locations
More Related Trials
-
Study of ONO-8539 in Patients With Overactive Bladder
NCT00876421 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment
NCT01122563 ·Status: COMPLETED
-
Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder
NCT02129816 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.
NCT00658684 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability
NCT01126424 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
NCT00966004 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
NCT00337090 ·Status: COMPLETED ·Phase: PHASE2
-
Study of ONO-8577 in Patients With Overactive Bladder
NCT03106623 ·Status: COMPLETED ·Phase: PHASE2
-
A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients
NCT00840645 ·Status: COMPLETED ·Phase: PHASE3
-
Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms
NCT00801944 ·Status: COMPLETED ·Phase: PHASE3
-
Antimuscarinic Treatment for Female Patients With Overactive Bladder Syndrome: Comparison of Daytime and Nighttime Dosing
NCT01819168 ·Status: COMPLETED
-
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
NCT01604928 ·Status: COMPLETED ·Phase: PHASE2
-
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
NCT02294396 ·Status: COMPLETED ·Phase: PHASE4
-
Reproducibility Study of Overactive Bladder Symptom Score [OABSS]
NCT01122550 ·Status: COMPLETED
-
Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome
NCT00239265 ·Status: COMPLETED ·Phase: PHASE3
-
Post Marketing Surveillance Study on Emselex After Launch in Germany
NCT00786448 ·Status: COMPLETED
-
Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis
NCT00629642 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00662909 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00912964 ·Status: COMPLETED ·Phase: PHASE3
-
Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome
NCT00239317 ·Status: COMPLETED ·Phase: PHASE3
-
Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.
NCT02501928 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker
NCT04693897 ·Status: UNKNOWN
-
Treatment of Hyperhidrosis With Oxybutynin
NCT01855256 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder
NCT00189800 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.
NCT00561951 ·Status: COMPLETED ·Phase: PHASE2